Skip to content

Emotion and Motivation in Patients With Psychosis

Influence of Emotion and Motivation on Behaviour and Neural Activity in Patients With Psychosis

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02853019
Enrollment
41
Registered
2016-08-02
Start date
2017-02-02
Completion date
2025-06-01
Last updated
2025-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Keywords

Emotion, motivation, cognition, schizophrenia

Brief summary

Anhedonia and avolition reflect emotional and motivational disorders, respectively. However, if these disorders play a major role in the symptomatology of schizophrenia, their mechanisms remain poorly understood, and existing treatments are inefficient on these symptoms. The literature suggests that the impairment does not concern emotion or motivation per se, but rather their influence on cognition. This project aims at using recent advances in the fundamental domain to better understand the cognitive and neuronal mechanisms of the patients' alterations, and especially how emotion and motivation influence cognition in schizophrenia.

Interventions

OTHERElectroencephalogram

electrophysiological measurements (evoked potentials) based on neural activity when visualizing stimuli

BEHAVIORALCognitive tasks

\- clinical scales and subjective assessments of emotional and motivational stimuli

BEHAVIORALsubjective evaluation scales

\- clinical scales and subjective assessments of emotional and motivational stimuli

Sponsors

Institut National de la Santé Et de la Recherche Médicale, France
CollaboratorOTHER_GOV
University Hospital, Strasbourg, France
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* diagnostic and Statistical Manual of Mental Disorders criteria for schizophrenia

Exclusion criteria

* addiction problem * invalidating visual sensory problems * neurological history * for the healthy volunteers: psychiatric history

Design outcomes

Primary

MeasureTime frameDescription
Change in the amplitude of the CNV (Contingent Negative Variation) as a function of the primer displayed on the screenDuring EEG sessions, at experimental session 1 (Day 0) and experimental session 2 (up to Day 120)Before each cognitive trial a primer will be displayed, which will be either neutral or convey emotion or motivation. The investigators will check whether this primer affects the subjects preparation by measuring the CNV, which is an evoked potential recorded with electroencephalography, and indexing preparatory effort.

Secondary

MeasureTime frameDescription
Change in the amplitude of the LPP (Late Positive Potential) as a function of the primer displayed on the screenDuring EEG sessions, at experimental session 1 (Day 0) and experimental session 2 (up to Day 120)The investigators will check whether primers affect the subjects attention by measuring the LPP, which is an evoked potential recorded with electroencephalography, and indexing sustained attention.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026